Clinical trials: HIV -1 Infection
HIV Infections
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.
- Trial name
- NCT00005002
- Testing
- Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
- Where
- United States
- Volunteers
- 688 people
- Sponsor
- Agouron Pharmaceuticals
HIV Infections
Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine
Human immunodeficiency virus (HIV) infection frequently involves combination drug therapy for its treatment; hence, it is important to understand their interactions and resulting changes in exposure which are associated with…
- Trial name
- NCT03836729
- Testing
- Tenofovir alafenamide/emtricitabine, GSK3640254
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF.
- Trial name
- NCT00002411
- Testing
- Nelfinavir mesylate, Lamivudine, Stavudine
- Where
- 32 sites in United States
- Sponsor
- Bristol-Myers Squibb
Infection, Human Immunodeficiency Virus I, HIV Infection
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
- Trial name
- NCT00044577
- Testing
- abacavir/lamivudine, abacavir, lamivudine
- Where
- 76 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- ViiV Healthcare
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
HIV Infection
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced…
- Trial name
- NCT00110877
- Testing
- LPV/rtv, TMC114/rtv
- Where
- 103 sites in United States, Argentina and 24 more
- Volunteers
- 604 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants.
- Trial name
- NCT02187107
- Testing
- TMC114, rtv
- Where
- 11 sites in Australia, Austria and 6 more
- Volunteers
- 52 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
This is an active control, randomized study to investigate the safety, tolerability and PK of repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM) (gluteus medius and vastus lateralis) and…
- Trial name
- NCT04484337
- Testing
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
The objective of the study is to compare two doses of MVA-nef vs. MVA-BN to induce Nef-specific cellular immune response in HIV-1 infected patients
- Trial name
- NCT00189930
- Testing
- MVA-nef, IMVAMUNE
- Where
- 5 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Bavarian Nordic
HIV Infections, AIDS
Test Albuvirtide in Experienced Patients
The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).
- Trial name
- TALENT (NCT02369965)
- Testing
- albuvirtide, lopinavir-ritonavir, tenofovir
- Where
- 12 sites in China
- Volunteers
- 418 people
- Sponsor
- Frontier Biotechnologies Inc.
Human Immunodeficiency Virus Infection
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
This is a double-blind Phase 2a study to test the safety and efficacy of an investigational HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once daily in HIV-1 infected antiretroviral…
- Trial name
- NCT01737359
- Testing
- amdoxovir 300 mg bid, amdoxovir 500 mg bid, tenofovir DF 300 mg qd
- Where
- 6 sites in Argentina
- Volunteers
- 2 people
- Sponsor
- RFS Pharma, LLC
HIV-1 Infection
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
The study will evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of a single dose of ulonivirine in antiretroviral therapy (ART)-naive, HIV-1 infected participants.
- Trial name
- NCT02174159
- Testing
- Ulonivirine
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy.
- Trial name
- NCT00053638
- Testing
- efavirenz, tenofovir, abacavir/lamivudine
- Where
- 58 sites in United States
- Volunteers
- 345 people
- Sponsor
- GlaxoSmithKline
HIV Infections
TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1
This is a 48-week study to compare TNX-355 plus OBT to placebo plus OBT in HIV subjects. You must have a stable viral load of at least 10,000 copies/ml, been treated with highly active antiretroviral therapy (HAART) for at least…
- Trial name
- NCT00089700
- Testing
- TNX-355
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Tanox
HIV Infections
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every 8 weeks (Q8W) compared to CAB…
- Trial name
- ATLAS-2M (NCT03299049)
- Testing
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension
- Where
- 119 sites in United States, Argentina and 11 more
- Volunteers
- 1,049 people
- Sponsor
- ViiV Healthcare
HIV Infections, HIV-1
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen…
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Trial name
- NCT00540449
- Testing
- TMC278, Efavirenz
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 694 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV I Infection
Charlotte Retention in Care Study
The objective of the Charlotte Retention in Care study is to assess if clinical decision support systems (CDSS) that produce standardized alerts for measures of retention in care across clinics in the city of Charlotte, North…
- Trial name
- NCT03584048
- Testing
- Alert to provider
- Where
- 4 sites in United States
- Volunteers
- 6,500 people
- Sponsor
- Epividian
HIV Infections
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.
- Trial name
- NCT00106379
- Testing
- Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF)
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
HIV Infections
Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Each year up to 22 million persons in the US are tested for HIV. Currently available "rapid" tests do not provide test results for at least 30 minutes from the collection of serum and plasma from the subject.
- Trial name
- NCT00514605
- Testing
- Behavioral counseling, HIV-1 Antibody Test Kit
- Where
- 14 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories